Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2860996 | 0.91 | TERT (0.45) | TERTMMEACECPA1ACE2 | |
| SCHEMBL2860992 | 0.91 | TERT (0.45) | TERTMMEACECPA1ACE2 | |
| SCHEMBL4086999 | 0.87 | TERT (0.38) | TERTMMEACECPA1ACE2 | |
| SCHEMBL4087537 | 0.86 | TERT (0.38) | TERTMMEACECPA1ACE2 | |
| SCHEMBL4087536 | 0.86 | TERT (0.38) | TERTMMEACECPA1ACE2 | |
| SCHEMBL4088259 | 0.82 | TERT (0.46) | TERTNMT2NMT1MMEACE | |
| SCHEMBL4088251 | 0.82 | TERT (0.46) | TERTNMT2NMT1MMEACE | |
| SCHEMBL30455467 | 0.80 | MME (0.50) | TERTNMT2NMT1MMEACE | |
| SCHEMBL31462095 | 0.79 | TERT (0.42) | TERTNMT2NMT1MMEACE | |
| SCHEMBL4099110 | 0.78 | OPRM1 (0.44) | TERTMMEOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | TERT 3633/4885NMT2 53/4885NMT1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.